SPC posts strong financial turnaround in 2025

Friday, 16 January 2026 00:20 - - {{hitsCtrl.values.hits}}

The State Pharmaceuticals Corporation of Sri Lanka (SPC) has registered an impressive improvement in its financial performance in 2025, marking one of its strongest years in recent history, according to its annual progress summary.

The SPC’s contribution to the Government through income tax and Treasury levies rose by 173% year-on-year (YoY) to Rs. 1.1 billion, compared with 2024. The Corporation also reported a 26% increase in revenue from its Own Revenue Stream (ORS) and a 9% rise in income from its State Osusala pharmacy network.

In a significant milestone, the SPC achieved full utilisation of its annual Budget allocation for supplies to the Department of Health Services (DHS) in 2025 through the issuance of indent orders, the first time this has been accomplished in the Corporation’s 53-year history. ORS production increased by 36% YoY, reflecting improved operational efficiency.

Revenue growth at State Osusala pharmacies was supported by the opening of five new outlets in Kiribathgoda, Narahenpita, Kegalle, Kalmunai, and Batticaloa, as well as efficiency improvements that enabled several previously loss-making outlets to return to profitability.

To further strengthen drug quality and safety standards, the SPC has initiated the ISO 17025 laboratory accreditation process. The Corporation has also expanded its corporate social responsibility (CSR) initiatives, including health camps and public awareness programs aimed at promoting rational medicine use and improved health practices.

As a major importer and supplier of pharmaceuticals, surgical consumables, laboratory chemicals, and equipment, the SPC continues to play a central role in supporting institutions under the Health Ministry. It also oversees the nationwide State Osusala network, ensuring public access to essential medicines at affordable prices.

All medicines distributed through the Osusala network undergo a rigorous four-stage quality testing process at the SPC’s laboratories before being released to the market, ensuring high standards of safety and efficacy.

Health Minister Dr. Nalinda Jayatissa, who conducted several inspections of SPC operations in 2025, acknowledged the Corporation’s achievements, while noting challenges faced by staff in a global pharmaceutical industry increasingly vulnerable to high-profit pressures and malpractice.

He reaffirmed the Government’s commitment to supporting SPC employees and safeguarding integrity in the sector.

SPC Chairman Dr. Manuj C. Weerasinghe, General Manager M.L. Subasinghe Arachchi, and the Board of Directors said the Corporation would continue to strengthen its operational network and pursue further progress in 2026.